Preclinical studies utilizing mouse models of melanoma and other cancers have revealed significant tumor control when combining LDRT with ICI, surpassing the efficacy of either treatment alone or in one such study using a B16 melanoma mouse model, LDRT treatment (50 cGy administered twice daily to a total dose of 500 cGy) notably enhanced the immunological response to PDL1 blockade. The gene discussed is CD274; the disease is melanoma.